RAIN News

12 IPOs raised $3.7 billion this past week, led by software maker UiPath (PATH), which raised more than $1 billion in its public debut. The pipeline remained active, with 11 IPOs and one direct listing submitting initial filings. SPAC activity continued to decline, with no pricings for the first week ever in 2021 and just four new filings. The largest deal...read more

Rain Therapeutics, a Phase 3-ready biotech developing in-licensed therapies for cancer, raised $125 million by offering 7.4 million shares at $17, the midpoint of the range of $16 to $18. At pricing, the company commands a fully diluted market value of $457 million.  Rain's lead candidate, RAIN-32, is a small molecule oral inhibitor of MDM2 in-licensed in...read more

Rain Therapeutics, a Phase 3-ready biotech developing in-licensed therapies for cancer, announced terms for its IPO on Monday. The Newark, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Rain Therapeutics would command a fully diluted market value of $457 million. Rain's lead...read more

Updated Monday, 4/19. 11 IPOs are scheduled to raise a total of $3.6 billion in the week ahead, led by software maker UiPath (PATH). The largest IPO of the week, UiPath (PATH) plans to raise $990 million at a $26.0 billion market cap. The company provides software that identifies automation opportunities across organizations....read more